BioMarin Pharmaceutical Inc.

Symbol: BMRN

NASDAQ

81.72

USD

Market price today

  • 75.1217

    P/E Ratio

  • -4.6075

    PEG Ratio

  • 15.52B

    MRK Cap

  • 0.00%

    DIV Yield

BioMarin Pharmaceutical Inc. (BMRN) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.77%

Operating Profit Margin

0.07%

Net Profit Margin

0.08%

Return on Assets

0.03%

Return on Equity

0.04%

Return on Capital Employed

0.03%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Alexander Hardy
Full-time employees:3401
City:San Rafael
Address:770 Lindaro Street
IPO:1999-07-26
CIK:0001048477

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.774% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.071%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.083%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.030% return, is a testament to BioMarin Pharmaceutical Inc.'s adeptness in optimizing resource deployment. BioMarin Pharmaceutical Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.042%. Furthermore, the proficiency of BioMarin Pharmaceutical Inc. in capital utilization is underscored by a remarkable 0.030% return on capital employed.

Stock Prices

BioMarin Pharmaceutical Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $83.98, while its low point bottomed out at $80.5. This variance in figures offers investors a lucid insight into the roller-coaster ride that is BioMarin Pharmaceutical Inc.'s stock market.

Liquidity Ratios

Analyzing BMRN liquidity ratios reveals its financial health of the firm. The current ratio of 274.38% gauges short-term asset coverage for liabilities. The quick ratio (154.77%) assesses immediate liquidity, while the cash ratio (68.66%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio274.38%
Quick Ratio154.77%
Cash Ratio68.66%

Profitability Ratios

BMRN profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 9.59% underscores its earnings before tax deductions. The effective tax rate stands at 13.44%, revealing its tax efficiency. The net income per EBT, 86.56%, and the EBT per EBIT, 135.10%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 7.10%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin9.59%
Effective Tax Rate13.44%
Net Income per EBT86.56%
EBT per EBIT135.10%
EBIT per Revenue7.10%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.74, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 388.54% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding155
Days of Inventory Outstanding743
Operating Cycle836.90
Days of Payables Outstanding388
Cash Conversion Cycle449
Receivables Turnover3.89
Payables Turnover0.94
Inventory Turnover0.49
Fixed Asset Turnover2.33
Asset Turnover0.36

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.48, and free cash flow per share, 0.86, depict cash generation on a per-share basis. The cash per share value, 5.54, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.11, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.48
Free Cash Flow per Share0.86
Cash per Share5.54
Operating Cash Flow Sales Ratio0.11
Free Cash Flow to Operating Cash Flow Ratio0.58
Cash Flow Coverage Ratio0.26
Short Term Coverage Ratio0.57
Capital Expenditure Coverage Ratio2.40
Dividend Paid and Capex Coverage Ratio2.40

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 15.83%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.21, we discern the balance between debt and equity financing. The long-term debt to capitalization, 10.47%, and total debt to capitalization, 17.66%, ratios shed light on its capital structure. An interest coverage of 10.23 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio15.83%
Debt Equity Ratio0.21
Long Term Debt to Capitalization10.47%
Total Debt to Capitalization17.66%
Interest Coverage10.23
Cash Flow to Debt Ratio0.26
Company Equity Multiplier1.35

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 12.88, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.89, reflects the portion of profit attributed to each share. The book value per share, 26.36, represents the net asset value distributed per share, while the tangible book value per share, 23.75, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share12.88
Net Income Per Share0.89
Book Value Per Share26.36
Tangible Book Value Per Share23.75
Shareholders Equity Per Share26.36
Interest Debt Per Share5.93
Capex Per Share-0.57

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 15.42%, indicates top-line expansion, while the gross profit growth, 14.25%, reveals profitability trends. EBIT growth, 173.86%, and operating income growth, 173.86%, offer insights into operational profitability progression. The net income growth, 18.43%, showcases bottom-line expansion, and the EPS growth, 17.11%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth15.42%
Gross Profit Growth14.25%
EBIT Growth173.86%
Operating Income Growth173.86%
Net Income Growth18.43%
EPS Growth17.11%
EPS Diluted Growth17.33%
Weighted Average Shares Growth1.39%
Weighted Average Shares Diluted Growth1.39%
Operating Cash Flow Growth-9.46%
Free Cash Flow Growth16.42%
10-Year Revenue Growth per Share223.48%
5-Year Revenue Growth per Share52.93%
3-Year Revenue Growth per Share25.17%
10-Year Operating CF Growth per Share295.86%
5-Year Operating CF Growth per Share642.90%
3-Year Operating CF Growth per Share79.58%
10-Year Net Income Growth per Share169.72%
5-Year Net Income Growth per Share304.67%
3-Year Net Income Growth per Share-81.10%
10-Year Shareholders Equity Growth per Share170.79%
5-Year Shareholders Equity Growth per Share57.27%
3-Year Shareholders Equity Growth per Share16.08%
Receivables Growth37.37%
Inventory Growth23.83%
Asset Growth7.32%
Book Value per Share Growth6.10%
Debt Growth4.70%
R&D Expense Growth14.96%
SGA Expenses Growth9.81%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 18,489,702,280, captures the company's total value, considering both debt and equity. Income quality, 0.95, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.19, gauges operational efficiency, while the research and development to revenue, 30.87%, highlights investment in innovation. The ratio of intangibles to total assets, 7.18%, indicates the value of non-physical assets, and capex to operating cash flow, -67.57%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value18,489,702,280
Income Quality0.95
Sales General and Administrative to Revenue0.19
Research and Development to Revenue30.87%
Intangibles to Total Assets7.18%
Capex to Operating Cash Flow-67.57%
Capex to Revenue-4.45%
Capex to Depreciation-103.09%
Stock-Based Compensation to Revenue8.56%
Graham Number23.01
Return on Tangible Assets2.64%
Graham Net Net1.13
Working Capital1,779,064,000
Tangible Asset Value4,460,649,000
Net Current Asset Value1,066,034,000
Average Receivables547,510,000
Average Payables273,373,500
Average Inventory1,000,633,000
Days Sales Outstanding96
Days Payables Outstanding200
Days of Inventory On Hand700
ROIC2.32%
ROE0.03%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.04, and the price to book ratio, 3.04, reflect the market's valuation relative to the company's book value. The price to sales ratio, 6.27, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 95.07, and price to operating cash flows, 55.09, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.04
Price to Book Ratio3.04
Price to Sales Ratio6.27
Price Cash Flow Ratio55.09
Price Earnings to Growth Ratio-4.61
Enterprise Value Multiple54.01
Price Fair Value3.04
Price to Operating Cash Flow Ratio55.09
Price to Free Cash Flows Ratio95.07
Price to Tangible Book Ratio3.66
Enterprise Value to Sales7.64
Enterprise Value Over EBITDA70.58
EV to Operating Cash Flow116.10
Earnings Yield0.93%
Free Cash Flow Yield0.29%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of BioMarin Pharmaceutical Inc. (BMRN) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 75.122 in 2024.

What is the ticker symbol of BioMarin Pharmaceutical Inc. stock?

The ticker symbol of BioMarin Pharmaceutical Inc. stock is BMRN.

What is company IPO date?

IPO date of BioMarin Pharmaceutical Inc. is 1999-07-26.

What is company current share price?

Current share price is 81.720 USD.

What is stock market cap today?

The market cap of stock today is 15516993600.000.

What is PEG ratio in 2024?

The current -4.607 is -4.607 in 2024.

What is the number of employees in 2024?

In 2024 the company has 3401.